Urokinase is more common drugs, belongs to a kind of medicine extracted
from human kidney development the organization of an enzyme protein, main effect
of the drug can be used in human blood clots or blood disease, can also be
effective treatment of human heart disease or myocardial infarction, etc., is
treated by means of the human body intravenous, is relatively safe drug.
indications
This product is mainly used for thrombolytic therapy of thromboembolic
diseases. These included acute generalized pulmonary embolism, coronary artery
embolism and myocardial infarction within 6-12 hours of chest pain, acute
cerebral vascular embolism with symptoms shorter than 3-6 hours, retinal artery
embolism and other peripheral artery embolism with severe iliac - femoral vein
thrombosis. It is also used to prevent thrombosis after the operation of
artificial heart valve, and to keep vascular intubation and drainage tube of
chest cavity and pericardium unobstructed. The efficacy of thrombolytic therapy
should be maintained by subsequent heparin anticoagulation.
This product is an enzymatic thrombolytic drug, which can activate the
conversion of plasminogen into plasminogen in vivo, and hydrolyze fibrin to
dissolve the freshly formed thrombus. Used for acute myocardial infarction,
acute cerebral thrombosis and cerebrovascular embolism, perilimb arteriovenous
thrombosis, central retinal arteriovenous thrombosis and other fresh thrombosis
occlusive diseases. This product has no obvious effect on old thrombus. It is
also suitable for the treatment of fresh thromboembolic diseases such as
cerebral thrombosis, peripheral vascular embolism, central retinal vascular
embolism, acute myocardial infarction, as well as renal transplantation, plastic
surgery and other thrombosis, all of which have good curative effect.
Usage.
Intravenous infusion or intravenous drip, 40 ~ 60 thousand u per day,
dissolved in 20 ~ 40ml normal saline for 1 time or 2-3 times; Or dissolve in 5%
glucose normal saline or 250ml low molecular dextran infusion. General 7 ~ 10
days for a course of treatment, or as appropriate increase or decrease.
1. Cerebrovascular diseases: within 6 hours to 6 days after the onset of
stroke symptoms of acute cerebral thrombosis, 60 thousand u intravenous infusion
or infusion is used.
2. Acute venous thrombosis: the first dose can be 60, 000-180, 000 u per
day, later 60, 000 u, twice a day, 7-10 days.
3. For acute arterial embolization thrombectomy, 60 thousand u of the
product was injected, and 60 thousand u was continued to be used after the
operation, twice a day for 5-7 days.
4. Acute myocardial infarction: half a million u dissolved in 25% glucose
solution 20ml medium intravenous infusion, and half a million u added to 5%
glucose solution 500ml medium intravenous infusion.
5. Ophthalmic application: daily intravenous infusion or push injection of
10,000 ~ 20,000 u, or 200 ~ 500u dissolved in 0.5ml of water for subconjunctival
or bulbar injection.
6. Coronary artery infusion: 200-1 million units can be dissolved in sodium
chloride injection or 20% ~ 60ml 5% glucose injection for intra-coronary
infusion at the rate of 120000 units per minute. The dose can be adjusted
according to the patient's weight, physical condition and thrombolytic
effect.